WO2007078271A3 - Lansoprazole orally disintegrating tablets - Google Patents

Lansoprazole orally disintegrating tablets Download PDF

Info

Publication number
WO2007078271A3
WO2007078271A3 PCT/US2005/046296 US2005046296W WO2007078271A3 WO 2007078271 A3 WO2007078271 A3 WO 2007078271A3 US 2005046296 W US2005046296 W US 2005046296W WO 2007078271 A3 WO2007078271 A3 WO 2007078271A3
Authority
WO
WIPO (PCT)
Prior art keywords
orally disintegrating
disintegrating tablets
lansoprazole
tablets
lansoprazole orally
Prior art date
Application number
PCT/US2005/046296
Other languages
French (fr)
Other versions
WO2007078271A2 (en
Inventor
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Capua Simona Di
Original Assignee
Teva Pharma
David Isaac Silver
Limor Ari-Pardo
Sivan Antler
Nava Shterman
Capua Simona Di
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, David Isaac Silver, Limor Ari-Pardo, Sivan Antler, Nava Shterman, Capua Simona Di filed Critical Teva Pharma
Priority to JP2008545558A priority Critical patent/JP2009519334A/en
Priority to CNA200580052347XA priority patent/CN101340897A/en
Priority to CA002630235A priority patent/CA2630235A1/en
Priority to PCT/US2005/046296 priority patent/WO2007078271A2/en
Priority to JP2008547591A priority patent/JP2009524592A/en
Priority to EP06848925A priority patent/EP1962844A2/en
Priority to CA002633825A priority patent/CA2633825A1/en
Priority to PCT/US2006/048961 priority patent/WO2007075980A2/en
Publication of WO2007078271A2 publication Critical patent/WO2007078271A2/en
Publication of WO2007078271A3 publication Critical patent/WO2007078271A3/en
Priority to IL191523A priority patent/IL191523A0/en
Priority to IL191923A priority patent/IL191923A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

The invention provides orally disintegrating tablets that readily disintegrates in the mouth, releasing enteric coated drug sub-tablets.
PCT/US2005/046296 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets WO2007078271A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2008545558A JP2009519334A (en) 2005-12-20 2005-12-20 Lansoprazole Orally Disintegrating Tablet
CNA200580052347XA CN101340897A (en) 2005-12-20 2005-12-20 Orally disintegrating tablet of lansoprazole
CA002630235A CA2630235A1 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
PCT/US2005/046296 WO2007078271A2 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets
EP06848925A EP1962844A2 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets
JP2008547591A JP2009524592A (en) 2005-12-20 2006-12-20 Lansoprazole Orally Disintegrating Tablet
CA002633825A CA2633825A1 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets
PCT/US2006/048961 WO2007075980A2 (en) 2005-12-20 2006-12-20 Lansoprazole orally disintegrating tablets
IL191523A IL191523A0 (en) 2005-12-20 2008-05-18 Lansoprazole orally disintegrating tablets
IL191923A IL191923A0 (en) 2005-12-20 2008-06-03 Lansoprazole orally disintegrating tablets

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/046296 WO2007078271A2 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets

Publications (2)

Publication Number Publication Date
WO2007078271A2 WO2007078271A2 (en) 2007-07-12
WO2007078271A3 true WO2007078271A3 (en) 2007-10-11

Family

ID=37672393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/046296 WO2007078271A2 (en) 2005-12-20 2005-12-20 Lansoprazole orally disintegrating tablets

Country Status (5)

Country Link
JP (1) JP2009519334A (en)
CN (1) CN101340897A (en)
CA (1) CA2630235A1 (en)
IL (1) IL191523A0 (en)
WO (1) WO2007078271A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
PE20141034A1 (en) * 2008-03-11 2014-09-10 Takeda Pharmaceutical SOLID ORAL DISINTEGRATION PREPARATION
CN101507718B (en) * 2009-03-03 2011-05-04 张登科 Sodium rabeprazole enteric-coated orally disintegrating tablets and preparation method thereof
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
EA028217B1 (en) * 2010-12-27 2017-10-31 Такеда Фармасьютикал Компани Лимитед Orally disintegrating tablet (variants)
CN102805737A (en) * 2012-09-03 2012-12-05 海南中化联合制药工业股份有限公司 Lansoprazole enteric oral disintegrating tablet and preparation method thereof
JP6364406B2 (en) * 2013-05-21 2018-07-25 武田薬品工業株式会社 Orally disintegrating tablets
EP3288556A4 (en) * 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP7336187B2 (en) * 2017-11-30 2023-08-31 日本ケミファ株式会社 Particulate pharmaceutical composition having multilayer structure

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US20040058018A1 (en) * 1996-01-04 2004-03-25 The Curators Of The University Of Missouri Novel substituted benzimidazole dosage forms and method of using same
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
WO2004091585A1 (en) * 2003-04-16 2004-10-28 Synthon B.V. Orally disintegrating tablets
US20040234594A1 (en) * 1995-02-09 2004-11-25 Per Johan Lundberg Pharmaceutical formulation and process
WO2005046634A2 (en) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Gastric juice-resistant form of administration
WO2005105049A2 (en) * 2004-04-19 2005-11-10 Eurand Pharmaceuticals Limited Orally disintegrating tablets and methods of manufacture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050214371A1 (en) * 2004-03-03 2005-09-29 Simona Di Capua Stable pharmaceutical composition comprising an acid labile drug

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234594A1 (en) * 1995-02-09 2004-11-25 Per Johan Lundberg Pharmaceutical formulation and process
US20040058018A1 (en) * 1996-01-04 2004-03-25 The Curators Of The University Of Missouri Novel substituted benzimidazole dosage forms and method of using same
WO1999059544A2 (en) * 1998-05-18 1999-11-25 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
EP1736144A2 (en) * 1998-05-18 2006-12-27 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
WO2004091585A1 (en) * 2003-04-16 2004-10-28 Synthon B.V. Orally disintegrating tablets
WO2005046634A2 (en) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Gastric juice-resistant form of administration
WO2005105049A2 (en) * 2004-04-19 2005-11-10 Eurand Pharmaceuticals Limited Orally disintegrating tablets and methods of manufacture

Also Published As

Publication number Publication date
CA2630235A1 (en) 2007-07-12
JP2009519334A (en) 2009-05-14
WO2007078271A2 (en) 2007-07-12
CN101340897A (en) 2009-01-07
IL191523A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
WO2007078271A3 (en) Lansoprazole orally disintegrating tablets
EG25188A (en) Device for the packaging and dispensing of solid shaped bodies, especially oral tablets or/and capsules.
ZA200704661B (en) Solid, orally appliance pharmaceutical administration forms containing rivaroxaban having modified release
AP2172A (en) Piping.
WO2007075980A8 (en) Lansoprazole orally disintegrating tablets
CA119221S (en) Blister package
TW200740432A (en) Solid dosage forms of valsartan and amlodipine and method of making the same
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
TNSN08538A1 (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2006138503A8 (en) New regimens for oral monophasic contraceptives
BRPI0820997A2 (en) Oral disintegration tablets comprising diphenhydramine.
EP1923074A4 (en) Orally disintegratable tablet
CA119774S (en) Blister package
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
CA118307S (en) Pasta dispenser disk
HK1122218A1 (en) Anticancer concomitant drug
WO2006046114A3 (en) Osmotic dosage forms providing ascending drug release, and processes for their preparation
AP2343A (en) Rapidly disintegrating taste-masked tablet.
ZA200408787B (en) Pharmaceutical combination.
ES1056676Y (en) ANTI-STRESS MOUTH.
GB2434894B8 (en) Triangular asynchronous replication.
CA116344S (en) Container for chewing gum
GB0417777D0 (en) Pharmaceutical combination
GB0502561D0 (en) The pill popper
ZA200501065B (en) The availability of commodities.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580052347.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2630235

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 191523

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 4668/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008545558

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05854934

Country of ref document: EP

Kind code of ref document: A2